 OSLO, Norway--BUSINESS WIRE--- ULTI Phase1--Ultimovacs ASA Ultimovacs, ticker ULTI, today announced positive five-year Overall Survival OS data from the Phase I trial evaluating the companys universal cancer vaccine, UV1, in combination with the checkpoint inhibitor, ipilimumab, in patients with metastatic malignant melanoma. After 5-years of follow-up, 50 of the patients in the open-label trial were still alive, providing encouraging signals of long-term survival benefit for UV1 in this late-stage 